Navigation Links
Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
Date:2/24/2010

ORLANDO, Fla., Feb. 24 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading consumer genomics biotech company, is pleased to report that the Superior Court of Pennsylvania has dismissed the appeal filed by the Company's former CEO and President, John DePhillipo, and his wife against the Company, its subsidiary GeneWize Life Sciences, Inc., and several of the Company's officers, directors and advisors.  The Court also awarded sanctions in favor of the GeneLink Parties against the DePhillipos and their counsel, with the amount of such sanctions to be determined in the future by the Court of Common Pleas of Pennsylvania, Philadelphia County.  

The DePhillipos' appeal arose from the May 5, 2009 Order and Opinion of the Court of Common Pleas of Pennsylvania, Philadelphia County wherein that Court dismissed the DePhillipos' claims as unviable.  

About GeneLink BioSciences, Inc.:

GeneLink Biosciences is a genomics, biotechnology, and wellness company engaged in genetic profile development, product development, business development and support services for its subsidiaries and distribution partners.  GeneLink's patented and patent pending technologies include proprietary genetic assessments and products linked to personalized health, beauty and wellness applications. For additional information, please visit www.genelinkbio.com.  

About GeneWize Life Sciences, Inc.:

GeneWize is a wholly owned subsidiary of GeneLink Biosciences and is the first network sales company to focus on providing individually customized nutritional and skin care formulations based on a consumer's personal DNA assessment.  The company's mission is to empower individuals to take personal responsibility and control of their health.  For additional information, please visit: www.genewize.com.

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE GeneLink, Inc.

Back to top

RELATED LINKS
http://www.genelinkbio.com

'/>"/>

SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Insmed to Appeal Delisting Notification From Nasdaq
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
7. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
8. Court of Appeals Overturns 2005 Patent Verdict Against Cordis
9. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
10. Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
11. Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... New Canaan, CT (PRWEB) , ... March 29, 2017 , ... ... of antibiotics and hormones in the world’s food supply through enhancement of the gut ... in the round included Connecticut Innovations , New York-based Sustainable Income Capital Management, ...
(Date:3/29/2017)... NEWARK, Del. , March 29, 2017 ... medicine company, and W. L. Gore & ... announced a collaborative research agreement whereby the two companies ... delivery device technologies that provide protection from immune rejection. ... has been developing innovative stem cell-derived cell replacement therapies ...
(Date:3/29/2017)... 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the ... new risk stratification test for breast cancer, via its ... ("IDL"). BreastSentry incorporates a blood-based biomarker test with a sophisticated ... developing breast cancer.   ... BreastSentry measures the fasting plasma levels of ...
(Date:3/29/2017)... -- The Global Microfluidic Chips Market by Manufacturers, Countries, ... comprehensive study on the existing state of the global Microfluidic Chips ... Europe and Asia-Pacific , ... Africa . ... Browse 172 Tables and Figures, 13 Major Company Profiles, ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity fraud. ... Used combined in one project, multi-biometric solutions ... ...
Breaking Biology News(10 mins):